{"a":[{"_":"Novartis’ centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test ","$":{"href":"/biotech/novartis-centerpiece-12b-avidity-buyout-flunks-crucial-phase-3-test","hreflang":"en"}}]}
Phase 3negativedel-desiranNegative
AI Analysis
Summary
Novartis' del-desiran, the centerpiece of its $12 billion acquisition of Avidity Biosciences, has failed the primary endpoint in the phase 3 Harbor trial, representing a significant setback for the Swiss drugmaker.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
missed primary endpoint in Harbor phase 3 trial
Importance:9/10
Sentiment:
-0.95
phase 3 failureacquisitionclinical trialdel-desiranHarbor trial
Read the original article
Published by FierceBiotech on September 8, 2026 3:35 AM